Core Viewpoint - The company announced the repurchase and cancellation of unvested restricted stock from its 2021 equity incentive plan, adjusting the repurchase price in the process [1][4][6]. Group 1: Decision Process and Disclosure - The board of directors and the supervisory board have approved the repurchase of unvested restricted stock through multiple meetings, ensuring compliance with legal and regulatory requirements [2][4][8]. - The company has publicly disclosed the names and positions of the intended recipients of the equity incentive plan, with no objections received during the public notice period [2][3]. Group 2: Repurchase Details - The repurchase is due to the failure to meet performance targets outlined in the equity incentive plan, affecting 140 individuals and corresponding to 25% of the total granted restricted stock [5][8]. - The total number of restricted stocks to be repurchased is 1,369,375 shares, which represents 18.82% of the total granted shares and 0.11% of the company's total share capital [6][8]. Group 3: Financial Impact and Future Arrangements - The repurchase will be funded through the company's own funds, amounting to a total of 11.8748 million yuan [6]. - Post-repurchase, the company's total share capital will decrease from 1,199,724,419 shares to 1,198,355,044 shares, with a reduction in restricted shares from 3,819,270 to 2,449,895 [6][8]. - The company will comply with relevant regulations for the cancellation process and will fulfill its information disclosure obligations [6][9].

Core Points - The company held its 11th Board of Directors' second meeting on August 27, 2025, where several key resolutions were passed [1] - The meeting was conducted in accordance with the Company Law of the People's Republic of China and the company's articles of association [1] Group 1: Financial Reports and Evaluations - The Board approved the "2025 Semi-Annual Report" and its summary, which had been reviewed by the Audit Committee and the Strategy and ESG Committee prior to the meeting [2] - The Board also approved the semi-annual evaluation report of the "Quality Improvement and Efficiency Enhancement Action Plan for 2025" [2] Group 2: Stock Incentive Plans - The Board approved the achievement of conditions for the fourth unlock period of the 2021 Restricted Stock Incentive Plan, allowing 29 eligible participants to unlock their restricted stocks [3] - The Board decided to adjust the repurchase prices for the restricted stocks under the 2021 Incentive Plan, reducing the repurchase price from 6.0415 CNY/share to 4.1015 CNY/share for the initial grant and from 6.0225 CNY/share to 4.0825 CNY/share for reserved grants [3][4] - The Board approved the repurchase and cancellation of 100.25 million shares of restricted stock due to performance evaluations and departures of certain incentive participants [5] Group 3: Future Plans and Proposals - The Board approved the adjustment of the repurchase price for the 2025 Restricted Stock Incentive Plan, with specific details to be disclosed [6] - The Board also approved the repurchase and cancellation of 20,000 shares of restricted stock for a participant who no longer meets the eligibility criteria due to departure [7] - The Board proposed to hold the second temporary shareholders' meeting of 2025 to discuss related matters, with details to be announced later [8]

Core Viewpoint - Jiangzhong Pharmaceutical Co., Ltd. is implementing a buyback and cancellation of certain restricted stocks as part of its 2021 stock incentive plan, which aims to enhance employee motivation and ensure sustainable development [1][5][10]. Summary by Sections Legal Framework - The legal opinion is based on the Company Law, Securities Law, and relevant regulations regarding stock incentive management [2][3]. - The law firm confirms that the company has provided all necessary and truthful documentation for the issuance of this legal opinion [3]. Buyback Authorization - The buyback plan has been approved by the company's board and is in compliance with the relevant legal requirements [4][10]. - The company aims to establish a long-term incentive mechanism to motivate core employees and does not harm the interests of the company or its shareholders [5][10]. Buyback Details - The buyback is due to certain employees no longer meeting the incentive conditions, resulting in the cancellation of 42,733 shares, which is 0.0067% of the total share capital [11]. - The adjusted buyback price is set at 2.0998 yuan per share, based on previous cash dividends [12][13]. - The total amount for the buyback is 89,730.75 yuan, sourced from the company's own funds [12][13]. Conclusion - The legal opinion concludes that the company has fulfilled the necessary legal procedures for the buyback and cancellation of shares, and further actions will be taken in accordance with relevant regulations [13].

Core Viewpoint - The company has decided to terminate the 2021 Restricted Stock Incentive Plan and cancel the repurchased shares, which will also lead to a reduction in registered capital due to changes in market conditions and the company's operational adjustments [1][3][6]. Group 1: Termination of Incentive Plan - The board of directors and the supervisory board have approved the termination of the 2021 Restricted Stock Incentive Plan and the cancellation of 10,408,656 repurchased shares [1][3]. - The decision to terminate the incentive plan was made after careful consideration, as the original performance targets were deemed unattainable under current market conditions [3][6]. Group 2: Share Repurchase and Capital Reduction - The company has repurchased a total of 10,408,656 shares, which represents approximately 0.79% of the total share capital, with a total expenditure of 34,112,473.58 yuan [2][5]. - Following the cancellation of the repurchased shares, the registered capital will decrease from 1,315,878,571 yuan to 1,305,469,915 yuan [5][6]. Group 3: Compliance and Approval Process - The termination of the incentive plan and the cancellation of shares will require approval from the shareholders' meeting [1][5][7]. - The supervisory board has confirmed that the actions taken are in compliance with relevant laws and regulations, ensuring no adverse impact on the company's operations or shareholder interests [7][8].

Core Points - The company held its 13th meeting of the 10th Supervisory Board on June 27, 2025, to discuss the achievement of conditions for the third release period of the 2021 Restricted Stock Incentive Plan [1] - The meeting approved the release of 37.98075 million shares of restricted stock for 519 incentive targets, confirming that the conditions for the release have been met and are in compliance with relevant laws and regulations [1][2] Summary by Sections Meeting Details - The meeting was conducted via communication methods with 5 supervisors participating in the vote, meeting legal and regulatory requirements [1] Incentive Plan - The 2021 Restricted Stock Incentive Plan's third release period conditions have been achieved, allowing for the legal and valid release of restricted stock for the designated incentive targets [1] - The approval was unanimous with 5 votes in favor and no votes against or abstentions [1]

Core Viewpoint - The company has completed the procedures for the third unlock period of the restricted stock incentive plan, allowing for the circulation of shares that were previously restricted [1][7]. Summary by Sections Incentive Plan Approval and Execution - The company has conducted the necessary approval procedures for the 2021 restricted stock incentive plan, including the review and approval of relevant proposals by the board and the supervisory committee [2][3]. - The initial grant of restricted stock involved 173 individuals, with a total of 1.6477 million shares granted, and the listing date for these shares was December 24, 2021 [2]. Unlocking Conditions and Performance Assessment - The third unlock period for the restricted stock is defined as the period from 42 months after the initial grant registration to the last trading day within 54 months from the grant date, allowing for 40% of the total granted shares to be unlocked [7]. - The company has confirmed that the conditions for unlocking the third period have been met, with 143 individuals eligible to unlock a total of 1,787,948 shares [7][18]. Changes in Share Structure - Following the unlocking of shares, the total number of shares with restrictions decreased from 77,083,531 to 75,295,583, while the total number of unrestricted shares increased from 151,904,648 to 153,692,596 [18]. - The total share capital of the company remains at 228,988,179 shares after the adjustments [18]. Adjustments to the Incentive Plan - The number of individuals participating in the incentive plan has been adjusted due to personal reasons leading to the forfeiture of shares by some participants, resulting in a reduction of the total granted shares [14][15]. - The company has also conducted buybacks of restricted shares from individuals who no longer qualify for the incentive plan due to leaving the company [5][16].

Core Viewpoint - The independent financial advisor report indicates that the conditions for the fourth vesting period of the initial grant and the third vesting period of the reserved grant under the 2021 restricted stock incentive plan of Aibo Medical have been met [1][12]. Summary by Sections Company Overview - Aibo Medical, officially known as Aibo Nord (Beijing) Medical Technology Co., Ltd., is involved in a restricted stock incentive plan aimed at motivating key personnel [1]. Incentive Plan Details - The initial grant's fourth vesting period is defined as the period from the first trading day after 48 months from the grant date to the last trading day within 60 months from the grant date, which is set from June 16, 2021, to June 15, 2026 [8]. - The reserved grant's third vesting period is defined as the period from the first trading day after 36 months from the reserved grant date to the last trading day within 48 months from the reserved grant date, set from March 31, 2025, to March 27, 2026 [11]. Performance Conditions - For the initial grant, the company must achieve an average compound growth rate of adjusted net profit of 35% for the year 2024, with the actual growth rate reported at 44.87%, thus meeting the performance target [10]. - The performance assessment for individual participants is categorized into four levels: Excellent, Good, Qualified, and Unqualified, determining the actual number of shares vested based on company and individual performance [10][11]. Approval Process - The incentive plan underwent several approval stages, including board meetings and shareholder meetings, with necessary independent opinions and verification from the supervisory board [6][7][8]. Independent Advisor's Opinion - The independent financial advisor confirms that the conditions for the vesting of the restricted stock have been fulfilled and that the relevant matters have received the necessary authorizations and approvals [12].

Core Viewpoint - The legal opinion letter from Deheheng Law Firm confirms that Beijing Huafeng Measurement and Control Technology Co., Ltd.'s stock incentive plan has met the necessary conditions for the fourth vesting period and the third reserved grant period, along with adjustments to the grant price and the cancellation of certain restricted stocks [1][8][14]. Group 1: Approval and Authorization of the Incentive Plan - The incentive plan has been approved and authorized through various resolutions, including the draft of the 2021 Restricted Stock Incentive Plan and the assessment management measures [4][5][6]. - Independent directors and the supervisory board have provided opinions confirming that the incentive plan is beneficial for the company's sustainable development and does not harm the interests of shareholders [4][6]. Group 2: Vesting Conditions - The first vesting period for the incentive plan is set from May 27, 2021, to May 26, 2026, with specific conditions that must be met for the vesting to occur [8][11]. - The conditions for vesting include the absence of negative audit opinions on financial reports and compliance with legal regulations regarding profit distribution [8][10]. Group 3: Adjustments to Grant Price - The grant price has been adjusted due to changes in the company's profit distribution plan, with the new adjusted price being 66.65 RMB per share [13][14]. - The adjustment method follows the formula where the new price is calculated based on the previous price minus the dividend per share [13]. Group 4: Cancellation of Restricted Stocks - A total of 18,136 shares of restricted stock have been canceled due to the departure of one incentive object and the voluntary relinquishment of another [14]. - The board and supervisory board have agreed that the cancellation complies with relevant laws and does not harm shareholder interests [14]. Group 5: Information Disclosure Obligations - The company is required to disclose relevant documents related to the vesting, adjustment, and cancellation of stocks within two trading days following the board meetings [14]. - The company will continue to fulfill its legal obligations for information disclosure as the incentive plan progresses [14].

证券代码：688617 证券简称：惠泰医疗 公告编号：2025-022 深圳惠泰医疗器械股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳惠泰医疗器械股份有限公司（以下简称"公司"）于 2025 年 5 月 13 日以现场结合通讯表决方式召开了第二届监事会第十九次会议，会议应到监事 3 人，实到监事 3 人，出席监事占应出席人数的 100%。本次监事会会议的召集、 召开程序符合《中华人民共和国公司法》等有关法律、行政法规、规范性文件和 《深圳惠泰医疗器械股份有限公司章程》的规定，会议决议合法有效。经与会监 事审议和表决，会议形成决议如下： 一、审议通过《关于作废2021年限制性股票激励计划部分已授予但尚未归 属的限制性股票的议案》 经审议，监事会认为：公司董事会根据 2021 年第一次临时股东大会的授权， 对作废 2021 年限制性股票激励计划部分已授予但尚未归属的限制性股票的审议 程序合法合规，符合《上市公司股权激励管理办法》等有关法律、法规、规范性 文件和《深圳惠泰医疗器械股份有限公司 2021 年限制 ...

Core Viewpoint - The legal opinion issued by Zhejiang Liuhe Law Firm confirms that Hangzhou Yongchuang Intelligent Equipment Co., Ltd. has met the necessary conditions for the release of restrictions on its 2021 restricted stock incentive plan, in compliance with relevant laws and regulations [2][12]. Group 1: Legal Framework and Approval Process - The law firm was commissioned to provide legal advice based on the Company Law, Securities Law, and the Management Measures for Incentive Plans [2]. - The company held multiple board and supervisory meetings to approve the incentive plan and its related matters, including the review of the incentive object list and the authorization for the board to handle related affairs [3][4][5][6][7][8]. - The independent directors provided their opinions supporting the implementation of the incentive plan [3][4][5]. Group 2: Conditions for Release of Restrictions - The release of restrictions is contingent upon meeting specific performance targets outlined in the incentive plan, which includes revenue and net profit growth rates compared to 2020 [13][14][15]. - The company reported a revenue of 3.146 billion yuan for 2023, meeting the performance target for the third release period of the incentive plan [15]. - The performance evaluation results for the 125 incentive objects were all rated as good or above, allowing for the full release of restrictions [15]. Group 3: Conclusion and Compliance - The law firm concluded that all necessary approvals and authorizations for the release of restrictions have been obtained, and the conditions set forth in the incentive plan have been satisfied [12][15]. - The release of restrictions aligns with the provisions of the Company Law, Securities Law, and the Management Measures for Incentive Plans [12].